CENPI Drives Breast Cancer Progression via Wnt/β-Catenin Modulation

Study Background and Research Question

Breast cancer remains the most prevalent malignancy among women, contributing significantly to global cancer mortality with approximately 2.3 million new cases and 665,000 deaths in 2022 (source: Wu et al., 2025). Despite advances in targeted therapies, challenges such as tumor heterogeneity and treatment resistance persist, limiting therapeutic efficacy. Chromosomal instability, particularly errors in chromosome segregation, is recognized as a hallmark of aggressive breast cancer subtypes, notably triple-negative breast cancer. Centromere proteins, essential for accurate chromosome segregation, are increasingly implicated in oncogenesis, yet the specific contributions of Centromere Protein I (CENPI) to breast cancer pathobiology had not been clearly defined prior to this study. Wu et al. (2025) set out to clarify the role of CENPI in breast cancer tumorigenesis, focusing on its impact on disease progression and underlying molecular mechanisms, particularly its potential interaction with the Wnt/β-catenin signaling axis (source: Wu et al., 2025).

Key Innovation from the Reference Study

The pivotal innovation of this study is the identification of CENPI as a critical oncogene in breast cancer. By integrating clinical data, molecular assays, and functional studies, the authors demonstrate that CENPI is not only overexpressed in breast cancer tissues but also actively drives tumor growth and malignant transformation through modulation of the Wnt/β-catenin signaling pathway. This mechanistic link positions CENPI as both a biomarker for disease progression and a potential therapeutic target, addressing the pressing need for novel molecular interventions in breast cancer (source: Wu et al., 2025).

Methods and Experimental Design Insights

Wu et al. employed a multi-tiered approach combining bioinformatics, in vitro functional assays, and in vivo xenograft models:

• Expression analysis: CENPI mRNA and protein levels were assessed in breast cancer tissues using The Cancer Genome Atlas (TCGA) datasets and immunohistochemical staining of clinical samples.
• Cellular functional assays: Manipulation of CENPI expression (overexpression and knockdown) in breast cancer cell lines enabled assessment of proliferation, migration, and invasion capabilities.
• Animal models: Mouse xenograft models were used to validate the effects of CENPI on tumor growth in vivo.
• Molecular mechanism interrogation: Transcriptomic profiling (RNA-Seq) and subsequent bioinformatics analyses identified downstream pathways. Western blotting and immunofluorescence validated activation of the Wnt/β-catenin axis.
• Transcriptional activity assays: Reporter assays such as the TOP/FOP flash system quantified β-catenin-driven transcriptional activity following CENPI modulation.

Of particular note, luciferase-based reporter assays—key for quantifying Wnt/β-catenin pathway activation—rely on sensitive detection of firefly luciferase substrate activity to measure transcriptional outputs in real time (source: internal_article_1).

Core Findings and Why They Matter

The study presents several notable findings:

• CENPI is aberrantly overexpressed in breast cancer tissues, and high expression correlates with advanced stage and poor prognosis (source: Wu et al., 2025).
• Functional impact: Overexpression of CENPI enhances proliferation, invasion, and migration of breast cancer cells in vitro, while knockdown inhibits these malignant phenotypes. Animal models corroborate these effects in vivo.
• Molecular mechanism: Transcriptome and protein analyses reveal that CENPI upregulates the Wnt/β-catenin pathway, a key driver of oncogenic processes. Activation is confirmed by increased β-catenin nuclear translocation and heightened transcriptional activity in TOP/FOP luciferase reporter assays.

These results position CENPI as a previously underappreciated driver of breast cancer progression, acting through a well-established oncogenic signaling cascade. The mechanistic insight that CENPI modulates Wnt/β-catenin signaling provides a rationale for targeting this axis in CENPI-high breast cancers.

Comparison with Existing Internal Articles

Several internal resources expand on the methodological and practical aspects of studying gene expression regulation using Dual Luciferase Reporter Gene Systems:

• The article "Dual Luciferase Reporter Gene System: Unraveling Transcri..." details the advantages of dual-reporter assays for dissecting complex signaling pathways, such as Wnt/β-catenin, in cancer models. The review emphasizes high-throughput luciferase detection and normalization to control for experimental variability, mirroring the reference study’s use of luciferase bioluminescence reporter assays for pathway activity quantification.
• "Decoding Gene Expression Regulation: Strategic Insights f..." discusses translational applications of dual reporter assays in cancer research, including scenarios directly relevant to CENPI-mediated modulation of oncogenic signaling. This article further contextualizes the reference study by illustrating how dual luciferase assay kits enable rigorous comparisons of transcriptional responses.
• Additionally, "Dual Luciferase Reporter Gene System: Precision in Gene E..." focuses on workflow optimization and reproducibility, both of which are critical in validating findings like those presented by Wu et al. (2025).

These internal resources complement the reference paper by providing practical guidance for implementing high-throughput, quantitative bioluminescence reporter assays in mammalian cell culture, ensuring robust and reproducible gene expression regulation studies.

Protocol Parameters

• assay | firefly luciferase substrate (luciferin) concentration | typically 0.5–2 mM | ensures optimal signal detection for gene expression studies in mammalian cells | workflow_recommendation
• assay | Renilla luciferase substrate (coelenterazine) concentration | typically 1–10 μM | allows reliable normalization in dual-reporter assays | workflow_recommendation
• assay | cell density for reporter transfection | 2–5 × 10⁴ cells/well (96-well format) | balances transfection efficiency and signal-to-noise ratio | workflow_recommendation
• assay | serum concentration in culture media | 1–10% | maintains cell viability and compatibility with luciferase detection | product_spec
• assay | detection wavelength | 550–570 nm (firefly), 480 nm (Renilla) | distinguishes between dual luciferase signals | product_spec
• assay | storage temperature for reagents | –20°C | preserves luciferase substrate stability for up to 6 months | product_spec

Limitations and Transferability

While Wu et al. (2025) provide strong evidence for CENPI's oncogenic function in breast cancer, several limitations merit consideration:

• Sample size: The immunohistochemical validation was performed on a limited number of clinical samples, which may restrict generalizability.
• Subtype representation: The study does not deeply stratify findings across all molecular subtypes of breast cancer, potentially overlooking context-specific effects.
• Model systems: Although both in vitro and in vivo models were used, the reliance on established cell lines and xenograft mice may not fully recapitulate patient tumor heterogeneity.

Transferability to other cancer types or mechanistic contexts should be approached cautiously until further validation is available. The Wnt/β-catenin pathway is broadly implicated in oncogenesis, but the direct relevance of CENPI beyond breast cancer remains to be established (source: Wu et al., 2025).

Research Support Resources

For researchers aiming to replicate or extend these findings, the use of a robust Dual Luciferase Reporter Gene System is essential for quantifying transcriptional regulation in mammalian cells. The Dual Luciferase Assay System (SKU: K1136) from APExBIO is compatible with commonly used culture media, offers highly sensitive detection of firefly and Renilla luciferase activity, and supports high-throughput bioluminescence reporter assays. Its design enables direct addition of luciferase reagents to cell culture, streamlining workflow and improving reproducibility—key considerations for studies investigating gene expression regulation and pathway modulation.